Search results
Showing 256 to 270 of 666 results for kidney or kidneys or renal
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]
Awaiting development Reference number: GID-TA11111 Expected publication date: TBC
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
View recommendations for AMR1Show all sections
This quality standard covers diagnosing and managing urinary tract infection in infants, children and young people (under 16). It includes new and recurrent infections of the upper or lower urinary tract. It describes high-quality care in priority areas for improvement.
View quality statements for QS36Show all sections
Sections for QS36
- Quality statements
- Quality statement 1: Presentation with unexplained fever of 38°C or higher
- Quality statement 2: History and examination – recording of risk factors
- Quality statement 3: Laboratory reporting – differentiation of E. coli and non-E. coli organisms
- Quality statement 4: Information about recognising re-infection
- Update information
- About this quality standard
MR-proADM test for use with clinical deterioration scores in cases of suspected infection (MIB195)
NICE has developed a medtech innovation briefing (MIB) on the MR-proADM test for use with clinical deterioration scores in cases of suspected infection .
COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)
This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations on care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.
Urinary tract infection (lower): antimicrobial prescribing (NG109)
This guideline sets out an antimicrobial prescribing strategy for lower urinary tract infection (also called cystitis) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
We have moved interventional procedures guidance 609 to become HealthTech guidance 468. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
NICE has developed a medtech innovation briefing (MIB) on fasciotens for abdominal wall closure .
SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (HTG400)
Evidence-based recommendations on the SepsiTest assay for rapidly identifying bloodstream bacteria and fungi.
effectiveness of 6-monthly imaging for 3 years for people with recurrent calcium renal or ureteric stones? Any explanatory notes(if...
Awaiting development Reference number: GID-TA11751 Expected publication date: TBC
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.
Read the biographies of our medical technologies advisory committee members.
Read the biographies of our medical technologies advisory committee members.
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.